in this issue
Chemical Week Magazine :: Business & Finance :: Europe/Mideast
Lonza and Teva discontinue biosimilars joint venture
7:16 AM MDT | August 23, 2013 | —Deepti Ramesh
Lonza and Teva Pharmaceutical Industries say that, following a strategic review, they have decided to discontinue their collaboration for the development, manufacturing, and marketing of biosimilars. Lonza and Teva established the biosimilars joint venture in 2009. Biosimilars are approved versions of innovator biopharmaceutical products, made after the innovator product’s patent...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee